A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis.
Clin Exp Rheumatol. 2018 Nov-Dec;36(6):1056-1060. Epub 2018 Jul 18.
Soubrier M1, Lambert C2, Combe B3, Gaudin P4, Thomas T5, Sibilia J6, Dougados M7, Dubost JJ8.
The Meta-analysis of Rheumatoid Artritis and Vitamin D
- Uric Acid associated with low vitamin D – Meta-analysis March 2019
- Widespread pain, arthritis pain and muscle pain are associated with low vitamin D – meta-analysis March 2018
- Rheumatic diseases not helped by Vitamin D – if you ignore what and how much was given – meta-analysis June 2017
- Rheumatoid Arthritis strongly associated with low vitamin D – meta-analysis April 2016
- Rheumatoid Arthritis associated with lower vitamin D and higher latitude – meta-analysis Jan 2016
- Rheumatoid arthritis is 40 percent more likely if vitamin D Receptor problem – 2 meta-analyses 2015
- Juvenile Rheumatoid Arthritis associated with low vitamin D, but how low – meta-analysis Jan 2013
- Rheumatoid arthritis 24 percent more likely if low vitamin D consumption– meta-analysis Sept 2012
Intervention AND Rheumatoid Arthritis
- Rheumatoid Arthritis pain reduced by monthly 100,000 IU of Vitamin D – Oct 2018
- Rheumatoid arthritis reduced by 440,000 IU of Vitamin D over 4 months – Oct 2015
- High dose vitamin reduced pain of fibromyalgia, osteoarthritis, and rheumatoid arthritis - July 2015
- Just 500 IU of vitamin D helped reduce rheumatoid arthritis pain - RCT Oct 2011
Additional supplements which look promising
(both also increase Vitamin D which gets to the tissue )
Omega-3 AND Rheumatoid Arthritis
Boron AND Rheumatoid Arthritis
OBJECTIVES: To evaluate the short-term efficacy of vitamin D (cholecalciferol) supplementation on functional disability in RA patients.
1) Patients: RA (ACR 1987 revised criteria) in non-remission (DAS28 >2.6) whose treatment was not expected to be changed over a 3-month period following inclusion and presenting with vitD deficits (serum 25OHD <30ng/mL). 2) Study design: prospective randomised placebo-controlled trial (NCT02243800). 3) Study arms: either vitD ampoules (cholecalciferol 100,000IU) or placebo. 4) Outcome measures: primary: improvement in patients' functional disability using the Health Assessment questionnaire (HAQ); secondary: improvement in DAS28ESR, DAS28CRP, ESR, CRP, RAID score, fatigue (EVA and FACIT), and SF36.
Overall, 59 patients were included, 83.1% females, aged 59.8±10.9 years on average, with RA for 17.0±9.7 years. Thirty patients received placebo and 29 vitD. At 6 months, HAQ scores tended to be increased in the placebo group (+0.08±0.25), while slightly numerically decreased in the vitD group (-0.03±0.23) (p=0.11). After adjusting for age, gender, season, and initial vitD status, the between-group difference achieved statistically significance (p=0.046). After adjusting for age, gender, season, and initial vitD status, there was no significant difference in the secondary criteria between the 2 groups except for ESR and CRP (p=0.002 and 0.04, respectively).
In this randomised, double-blind, placebo-controlled clinical trial in patients with RA and VitD deficiency, high doses of cholecalciferol resulted in a statistically significant improvement in functional disability at month 6, which, however, was clinically not relevant.